ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$853.40
-50.35 (-5.57%)
▼
5d:
-3.48%
30d:
+4.56%
90d:
+25.16%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ARGX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ARGX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1549.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$962.33
11.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $853.40, which is considered fair relative to its 30-day fair value range of $807.87 to $884.41. The stock's valuation (Forward PE: 28.4) is in line with its historical norms (28.1). At these levels, the market is pricing in 0.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ARGX is in a uptrend. The price is currently testing key support at $842.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: ARGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1018.84 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARGX is in a uptrend. The price is currently testing key support at $842.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: ARGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1018.84 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$807.87 -
$884.41
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading below Wall St target ($1018.84)
- NEUTRAL: Market pricing in 0.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$807.87 -
$884.41
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$842.22
Resistance Level
$933.99
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.39
Wall Street Target
$1018.84
(+12.7%)
Revenue Growth (YoY)
62.6%
Earnings Growth (YoY)
114.0%
Profit Margin
31.4%
Valuation Premium vs History
+0.3% premium
PE vs Historical
28.4 vs 28.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.3%
(market-implied from PE analysis)
1-Year Target
$906.46
(+0%)
2-Year Target
$909.18
(+1%)
3-Year Target
$911.91
(+1%)
3-Yr Target (if PE normalizes)
(PE: 28→28)
PE COMPRESSION
$902.64
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.4, Growth: 44.4%)
$2721.44
(+201%)
Base:
(SPY PE: 21.8, Growth: 44.4%)
$2087.91
(+131%)
Bear:
(PE: 18.5, Growth: 44.4%)
$1774.72
(+96%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Trailing PE: 40.20 | Current EPS (TTM): $22.47
Bull Case
$1407.73
(+56%)
Analyst growth 41.7%, PE expands to 44.2
Base Case
$1279.75
(+42%)
Market implied 41.7%, PE stable at 40.2
Bear Case
$614.23
(-32%)
Severe decline -20.0%, PE contracts to 34.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 4:39 PM ET
Data refreshes hourly during market hours. Next update: 5:39 PM
Data refreshes hourly during market hours. Next update: 5:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
